DiaMedica Therapeutics Inc DMAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DMAC is a good fit for your portfolio.
News
-
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
-
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
-
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
-
Diamedica Therapeutics to Resume Stroke Treatment Trials After FDA Removes Hold
Trading Information
- Previous Close Price
- $2.65
- Day Range
- $2.73–2.81
- 52-Week Range
- $1.46–4.75
- Bid/Ask
- $2.61 / $2.77
- Market Cap
- $105.14 Mil
- Volume/Avg
- 20,711 / 44,254
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 19
- Website
- https://www.diamedica.com
Comparables
Valuation
Metric
|
DMAC
|
DYN
|
CBAY
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.97 | 19.19 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
DMAC
DYN
CBAY
Financial Strength
Metric
|
DMAC
|
DYN
|
CBAY
|
---|---|---|---|
Quick Ratio | 19.12 | 2.41 | 10.70 |
Current Ratio | 19.27 | 2.53 | 10.96 |
Interest Coverage | — | — | −5.27 |
Quick Ratio
DMAC
DYN
CBAY
Profitability
Metric
|
DMAC
|
DYN
|
CBAY
|
---|---|---|---|
Return on Assets (Normalized) | −37.95% | −88.69% | −30.06% |
Return on Equity (Normalized) | −40.26% | −114.25% | −51.97% |
Return on Invested Capital (Normalized) | −39.87% | −102.56% | −30.87% |
Return on Assets
DMAC
DYN
CBAY
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dgnkqgdkl | Zdlbt | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ntsnlkn | Qywrvg | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bkmkwlwkq | Sknflt | $106.1 Bil | |
MRNA
| Moderna Inc | Bqkbkysn | Bfzx | $42.3 Bil | |
ARGX
| argenx SE ADR | Ssdtcjpjz | Vdwn | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Bsdxkvf | Zxbd | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hxymrsjry | Wqsjsd | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yllmgmdb | Bxzfrh | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qfbdfyyvm | Mdgvt | $13.6 Bil | |
INCY
| Incyte Corp | Ygjjcqgr | Rfkfq | $12.8 Bil |